Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Sarissa Capital Management announced a significant victory against the Amarin Corporation board, claiming to have received nearly 80% of shareholder votes in favor of their slate. This vote represents more than 100 million additional votes than the incumbent board. Sarissa, the largest shareholder, expresses confidence in leveraging Vascepa, a unique and beneficial drug, to unlock shareholder value. Sarissa emphasizes the importance of running Amarin for the benefit of all shareholders and urges further action.
Amarin Corporation plc (NASDAQ: AMRN) announced the preliminary results of its 2023 General Meeting of Shareholders, where shareholders voted to elect seven nominees from Sarissa and remove Per Wold-Olsen as Chairman of the Board, effective immediately. The Board will expand to 15 directors, with a new Chairman to be appointed later. Amarin acknowledged the feedback from shareholders and remains focused on its strategy amidst ongoing pricing negotiations in Europe and stabilization efforts in the U.S. The final voting results will be certified and reported on a Form 8-K.
Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus have entered an exclusive licensing agreement for VAZKEPA's distribution in Australia and New Zealand. This partnership positions CSL Seqirus, known for its strong market access capabilities, to manage pricing and reimbursement while promoting the treatment for cardiovascular disease. Amarin will receive an upfront payment and potential milestone payments totaling up to $12 million. Approximately 1.3 million patients in Australia have cardiovascular disease, highlighting a significant market opportunity for VAZKEPA.
Amarin Corporation (NASDAQ: AMRN) responded to Sarissa's claims regarding management compensation. The Board clarified that the 2023 compensation plan was approved in February, consistent with prior years, and includes performance-based grants for all employees, including CEO Karim Mikhail. Amarin emphasized that the General Meeting has not yet occurred and that results will be published post-meeting, adhering to SEC guidelines. The company asserts its commitment to transitioning into a diversified cardiometabolic entity and executing its strategic plan to enhance value for shareholders.
Amarin Corporation (NASDAQ:AMRN) has announced that data from the REDUCE-IT trial will be presented at the ACC.23/WCC in New Orleans, March 4-6, 2023. This includes research on the efficacy of VASCEPA/VAZKEPA (icosapent ethyl) in patients who recently experienced acute coronary syndrome. Key presentations include analyses on EPA and its role in cardiovascular risk reduction. Amarin's Chief Medical Officer highlighted that these findings enhance the understanding of icosapent ethyl's utility in treating high-risk cardiovascular patients and compared EPA's antioxidant effects against other oils. The conference will feature multiple presentations sharing critical insights on cardiovascular health.
Sarissa Capital Management accuses the Amarin board of bad faith for approving substantial equity grants to executives, including Karim Mikhail, just before a crucial proxy contest. The board awarded over 3.6 million shares, with Mikhail receiving 70% more than last year, despite the company's poor performance. Sarissa claims these grants circumvented fiduciary duties and lacked performance criteria, questioning the board's integrity during a contested election. They demand Mikhail return these grants to employees, arguing that board actions reflect ongoing mismanagement, jeopardizing shareholder interests. Sarissa aims to hold directors accountable and initiate board reform.
Amarin Corporation plc (NASDAQ:AMRN) announced its president and CEO, Karim Mikhail, will participate in the Cowen Annual Health Care Conference from March 6-8, 2023, in Boston. Mikhail's presentation is scheduled for March 8, 2023, at 1:30 p.m. ET. The conference will be available via live webcast, which will also be archived on the company’s website. Amarin is dedicated to advancing cardiovascular disease management through innovation and research, and they maintain a global presence with offices in the U.S., Ireland, and Switzerland.
Sarissa Capital Management LP urges Amarin Corporation plc (NASDAQ: AMRN) shareholders to vote in favor of board changes at the company. The call to action is aimed at removing Chairman Per Wold-Olsen, whom Sarissa accuses of causing significant value destruction due to operational failures. Sarissa, as the largest shareholder, emphasizes its commitment to creating value and has proposed qualified nominees for the board. Shareholders must submit their votes by midnight (New York Time) today to ensure they count for the upcoming meeting on February 28, 2023. More information can be found on Sarissa's proxy website.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on March 1, 2023, at 8:00 a.m. ET, to discuss its fourth quarter and year-end 2022 financial results. This call will follow the pre-market release of the financial results. Investors can access the live call via the company's investor relations website or dial in using designated numbers. A replay will also be available shortly after the call and for a year thereafter. Amarin is focused on advancing cardiovascular disease management through scientific research and clinical trials, with offices in various locations globally.
Sarissa Capital Management expressed strong concerns regarding Amarin Corporation (NASDAQ: AMRN) leadership, urging shareholders to vote for change in the upcoming meeting. Sarissa claims that current management has significantly reduced shareholder value and mismanaged the company's assets, particularly the valuable drug Vascepa/Vazkepa. With a track record of 39.7% average performance in their portfolio, Sarissa aims to improve Amarin's fortunes. The meeting is scheduled for February 28, 2023, with a voting deadline of February 21, 2023. Sarissa advocates for the removal of Chairman Per Wold-Olsen.